+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Generic Drugs Market - Global Forecast 2026-2032- Product Image
Generic Drugs Market - Global Forecast 2026-2032- Product Image
New

Generic Drugs Market - Global Forecast 2026-2032

  • PDF Icon

    Report

  • 194 Pages
  • January 2026
  • Region: Global
  • 360iResearch™
  • ID: 5888623
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

The generic drugs market plays a pivotal role for healthcare executives worldwide, addressing the intersecting challenges of affordability, regulatory compliance, and sustainable supply of essential medicines. As competitive pressures rise and value-based care models mature, decision-makers face complex strategic choices across product lifecycle, distribution, and risk management.

Market Snapshot: Generic Drugs Market Size and Growth

The global generic drugs market expanded from USD 359.35 billion in 2024 to USD 392.73 billion in 2025, and is projected to reach USD 731.02 billion by 2032, reflecting a compound annual growth rate (CAGR) of 9.28%. This robust growth signals strong alignment between clinical demand, regulatory dynamics, and economic priorities. Generic pharmaceuticals are taking an increasingly pivotal position throughout international healthcare supply networks, providing strategic entry points across both developed and emerging markets.

Scope & Segmentation of the Generic Drugs Market

  • Product Types: Over-the-Counter (OTC) Generic Drugs and Prescription Generic Drugs shape different operational and commercial frameworks for manufacturers, depending on regulatory and prescribing contexts.
  • Drug Classes: Major categories include Analgesics, Antibiotics, Antidepressants, Antidiabetics, Antihistamines, and Antihypertensives, each responding to distinctive clinical indications, therapeutic substitution rates, and stewardship protocols.
  • Routes of Administration: The market encompasses Inhalations, Injectables, Oral, and Topical formulations, each demanding unique manufacturing practices and affecting logistics and capital allocations.
  • Patient Demographics: Segments address Adult, Geriatric, and Pediatric groups, requiring tailored dosage forms, adherence solutions, and efficacy validation approaches for distinct patient needs.
  • Therapeutic Applications: Core applications span Cardiovascular, Central Nervous System, Diabetes, Oncology, Respiratory, and Anti-infectives, influencing time-to-market, lifecycle management, and portfolio diversification strategies.
  • Distribution Channels: Offline distribution via Hospital Pharmacies and Retail Pharmacies, as well as Online Pharmacies, influence access, inventory control approaches, and channel partner dynamics.
  • Regions: Americas, Europe, Middle East & Africa, and Asia-Pacific each present diverse regulatory landscapes, supply chain considerations, and competitive pressures, shaping global and localized business models.
  • Enabling Technologies: Innovations such as continuous processing, digitized quality control, and advanced supply chain analytics increasingly drive manufacturing productivity, regulatory adherence, and consistent distribution.

Key Takeaways for Senior Decision-Makers

  • Generic drugs enable broader access to essential therapies after brand patent expirations, making them integral to controlling treatment costs and improving outcomes.
  • New manufacturing technologies—in areas such as digital quality management and local capacity expansion—are improving operational robustness and reliability for suppliers and distributors.
  • Compliance is increasingly complex, as regulatory harmonization requires enhanced investments in analytics, comprehensive documentation, and post-market surveillance to maintain market position and ensure ongoing approvals.
  • Continued evolution of commercial models underscores the need for integrated supply chain functions, optimized digital sales channels, and value-based contracting to capture differentiated growth opportunities.
  • Global players face increasing need for regional customization, addressing diverse reimbursement regimes, competition, and compliance standards for locally relevant strategies.
  • Service differentiation—such as assured cold chain support, targeted adherence programs, and high-quality regulatory dossiers—strengthens competitive positioning and stakeholder trust.

Tariff Impact: U.S. Trade Policy Shaping Sourcing and Procurement

U.S. tariff changes effective in 2025 led manufacturers and distributors to expand and diversify their sourcing networks, including greater investment in domestic and regional production. These changes prompted enhancements in inventory management and tighter procurement collaboration among supply partners. Scrutiny of contracting processes has increased, with operational agility and risk management taking precedence in sourcing and supply strategies for generic drugs.

Methodology & Data Sources Used in This Generic Drugs Market Analysis

This research is founded on interviews with manufacturing, distribution, regulatory, and payer professionals. It is further supported by comprehensive reviews of technical literature, regulatory documentation, and key trade publications. Cross-region analysis and strict confidentiality protocols ensured robust, actionable findings suitable for high-level executive planning.

Why This Report Matters for Executives in the Generic Drugs Market

  • The report enables evidence-based decisions by illustrating how evolving regulations, advanced technologies, and trade trends create both risks and opportunities.
  • It supports leaders in optimizing strategies across commercial, portfolio, and regulatory functions—highlighting adaptation needs for different regions and evolving market demands.
  • Actionable insights allow for prioritization of manufacturing and supply chain investments necessary to maintain compliance and secure future competitiveness in complex environments.

Conclusion: Balancing Affordability, Quality, and Supply Resilience

The generic drugs industry relies on executive leadership to maintain effective cost, compliance, and supply chain strategies. Forward-looking investments and adaptable business models support long-term reliability and market confidence.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Definition
1.3. Market Segmentation & Coverage
1.4. Years Considered for the Study
1.5. Currency Considered for the Study
1.6. Language Considered for the Study
1.7. Key Stakeholders
2. Research Methodology
2.1. Introduction
2.2. Research Design
2.2.1. Primary Research
2.2.2. Secondary Research
2.3. Research Framework
2.3.1. Qualitative Analysis
2.3.2. Quantitative Analysis
2.4. Market Size Estimation
2.4.1. Top-Down Approach
2.4.2. Bottom-Up Approach
2.5. Data Triangulation
2.6. Research Outcomes
2.7. Research Assumptions
2.8. Research Limitations
3. Executive Summary
3.1. Introduction
3.2. CXO Perspective
3.3. Market Size & Growth Trends
3.4. Market Share Analysis, 2024
3.5. FPNV Positioning Matrix, 2024
3.6. New Revenue Opportunities
3.7. Next-Generation Business Models
3.8. Industry Roadmap
4. Market Overview
4.1. Introduction
4.2. Industry Ecosystem & Value Chain Analysis
4.2.1. Supply-Side Analysis
4.2.2. Demand-Side Analysis
4.2.3. Stakeholder Analysis
4.3. Porter’s Five Forces Analysis
4.4. PESTLE Analysis
4.5. Market Outlook
4.5.1. Near-Term Market Outlook (0-2 Years)
4.5.2. Medium-Term Market Outlook (3-5 Years)
4.5.3. Long-Term Market Outlook (5-10 Years)
4.6. Go-to-Market Strategy
5. Market Insights
5.1. Consumer Insights & End-User Perspective
5.2. Consumer Experience Benchmarking
5.3. Opportunity Mapping
5.4. Distribution Channel Analysis
5.5. Pricing Trend Analysis
5.6. Regulatory Compliance & Standards Framework
5.7. ESG & Sustainability Analysis
5.8. Disruption & Risk Scenarios
5.9. Return on Investment & Cost-Benefit Analysis
6. Cumulative Impact of United States Tariffs 2025
7. Cumulative Impact of Artificial Intelligence 2025
8. Generic Drugs Market, by Product Type
8.1. Over-the-Counter (OTC) Generic Drugs
8.2. Prescription Generic Drugs
9. Generic Drugs Market, by Drug Class
9.1. Analgesics
9.2. Antibiotics
9.3. Antidepressants
9.4. Antidiabetics
9.5. Antihistamines
9.6. Antihypertensives
10. Generic Drugs Market, by Route of Administration
10.1. Inhalations
10.2. Injectables
10.3. Oral
10.4. Topical
11. Generic Drugs Market, by Patient Type
11.1. Adult
11.2. Geriatric
11.3. Pediatric
12. Generic Drugs Market, by Therapeutic Area
12.1. Cardiovascular Diseases
12.1.1. Hypertension
12.1.2. Dyslipidemia
12.1.3. Heart Failure
12.2. Central Nervous System Disorders
12.2.1. Depression & Anxiety
12.2.2. Epilepsy
12.2.3. Schizophrenia & Psychosis
12.3. Oncology
12.3.1. Solid Tumors
12.3.2. Hematologic Malignancies
12.4. Anti-Infective Diseases
12.4.1. Bacterial Infections
12.4.2. Viral Infections
12.4.3. Fungal Infections
12.4.4. Parasitic Infections
12.5. Respiratory Diseases
12.5.1. Asthma
12.5.2. Chronic Obstructive Pulmonary Disease
12.5.3. Allergic Rhinitis
12.6. Gastrointestinal Disorders
12.7. Dermatological Disorders
12.8. Hematology
13. Generic Drugs Market, by Distribution Channel
13.1. Offline
13.1.1. Hospital Pharmacies
13.1.2. Retail Pharmacies
13.2. Online
13.2.1. Business-To-Business Platforms
13.2.2. Business-To-Consumer Platforms
14. Generic Drugs Market, by Region
14.1. Americas
14.1.1. North America
14.1.2. Latin America
14.2. Europe, Middle East & Africa
14.2.1. Europe
14.2.2. Middle East
14.2.3. Africa
14.3. Asia-Pacific
15. Generic Drugs Market, by Group
15.1. ASEAN
15.2. GCC
15.3. European Union
15.4. BRICS
15.5. G7
15.6. NATO
16. Generic Drugs Market, by Country
16.1. United States
16.2. Canada
16.3. Mexico
16.4. Brazil
16.5. United Kingdom
16.6. Germany
16.7. France
16.8. Russia
16.9. Italy
16.10. Spain
16.11. China
16.12. India
16.13. Japan
16.14. Australia
16.15. South Korea
17. United States Generic Drugs Market
18. China Generic Drugs Market
19. Competitive Landscape
19.1. Market Concentration Analysis, 2024
19.1.1. Concentration Ratio (CR)
19.1.2. Herfindahl Hirschman Index (HHI)
19.2. Recent Developments & Impact Analysis, 2024
19.3. Product Portfolio Analysis, 2024
19.4. Benchmarking Analysis, 2024
19.5. Abbott Laboratories
19.6. Aurobindo Pharma Limited
19.7. Cipla Limited
19.8. Dr. Reddy’s Laboratories Ltd.
19.9. Fresenius SE & Co. KGaA
19.10. Pfizer, Inc.
19.11. Sandoz Group AG
19.12. Sanofi SA
19.13. Sun Pharmaceutical Industries Limited
19.14. Teva Pharmaceutical Industries Ltd.
19.15. Viatris Inc.
List of Figures
FIGURE 1. GLOBAL GENERIC DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 2. GLOBAL GENERIC DRUGS MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 3. GLOBAL GENERIC DRUGS MARKET, FPNV POSITIONING MATRIX, 2024
FIGURE 4. GLOBAL GENERIC DRUGS MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
FIGURE 5. GLOBAL GENERIC DRUGS MARKET SIZE, BY DRUG CLASS, 2024 VS 2025 VS 2032 (USD MILLION)
FIGURE 6. GLOBAL GENERIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2025 VS 2032 (USD MILLION)
FIGURE 7. GLOBAL GENERIC DRUGS MARKET SIZE, BY PATIENT TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
FIGURE 8. GLOBAL GENERIC DRUGS MARKET SIZE, BY THERAPEUTIC AREA, 2024 VS 2025 VS 2032 (USD MILLION)
FIGURE 9. GLOBAL GENERIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2032 (USD MILLION)
FIGURE 10. GLOBAL GENERIC DRUGS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
FIGURE 11. GLOBAL GENERIC DRUGS MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
FIGURE 12. GLOBAL GENERIC DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
FIGURE 13. UNITED STATES GENERIC DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 14. CHINA GENERIC DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
List of Tables
TABLE 1. GLOBAL GENERIC DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 2. GLOBAL GENERIC DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
TABLE 3. GLOBAL GENERIC DRUGS MARKET SIZE, BY OVER-THE-COUNTER (OTC) GENERIC DRUGS, BY REGION, 2018-2032 (USD MILLION)
TABLE 4. GLOBAL GENERIC DRUGS MARKET SIZE, BY OVER-THE-COUNTER (OTC) GENERIC DRUGS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 5. GLOBAL GENERIC DRUGS MARKET SIZE, BY OVER-THE-COUNTER (OTC) GENERIC DRUGS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 6. GLOBAL GENERIC DRUGS MARKET SIZE, BY PRESCRIPTION GENERIC DRUGS, BY REGION, 2018-2032 (USD MILLION)
TABLE 7. GLOBAL GENERIC DRUGS MARKET SIZE, BY PRESCRIPTION GENERIC DRUGS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 8. GLOBAL GENERIC DRUGS MARKET SIZE, BY PRESCRIPTION GENERIC DRUGS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 9. GLOBAL GENERIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 10. GLOBAL GENERIC DRUGS MARKET SIZE, BY ANALGESICS, BY REGION, 2018-2032 (USD MILLION)
TABLE 11. GLOBAL GENERIC DRUGS MARKET SIZE, BY ANALGESICS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 12. GLOBAL GENERIC DRUGS MARKET SIZE, BY ANALGESICS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 13. GLOBAL GENERIC DRUGS MARKET SIZE, BY ANTIBIOTICS, BY REGION, 2018-2032 (USD MILLION)
TABLE 14. GLOBAL GENERIC DRUGS MARKET SIZE, BY ANTIBIOTICS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 15. GLOBAL GENERIC DRUGS MARKET SIZE, BY ANTIBIOTICS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 16. GLOBAL GENERIC DRUGS MARKET SIZE, BY ANTIDEPRESSANTS, BY REGION, 2018-2032 (USD MILLION)
TABLE 17. GLOBAL GENERIC DRUGS MARKET SIZE, BY ANTIDEPRESSANTS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 18. GLOBAL GENERIC DRUGS MARKET SIZE, BY ANTIDEPRESSANTS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 19. GLOBAL GENERIC DRUGS MARKET SIZE, BY ANTIDIABETICS, BY REGION, 2018-2032 (USD MILLION)
TABLE 20. GLOBAL GENERIC DRUGS MARKET SIZE, BY ANTIDIABETICS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 21. GLOBAL GENERIC DRUGS MARKET SIZE, BY ANTIDIABETICS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 22. GLOBAL GENERIC DRUGS MARKET SIZE, BY ANTIHISTAMINES, BY REGION, 2018-2032 (USD MILLION)
TABLE 23. GLOBAL GENERIC DRUGS MARKET SIZE, BY ANTIHISTAMINES, BY GROUP, 2018-2032 (USD MILLION)
TABLE 24. GLOBAL GENERIC DRUGS MARKET SIZE, BY ANTIHISTAMINES, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 25. GLOBAL GENERIC DRUGS MARKET SIZE, BY ANTIHYPERTENSIVES, BY REGION, 2018-2032 (USD MILLION)
TABLE 26. GLOBAL GENERIC DRUGS MARKET SIZE, BY ANTIHYPERTENSIVES, BY GROUP, 2018-2032 (USD MILLION)
TABLE 27. GLOBAL GENERIC DRUGS MARKET SIZE, BY ANTIHYPERTENSIVES, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 28. GLOBAL GENERIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 29. GLOBAL GENERIC DRUGS MARKET SIZE, BY INHALATIONS, BY REGION, 2018-2032 (USD MILLION)
TABLE 30. GLOBAL GENERIC DRUGS MARKET SIZE, BY INHALATIONS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 31. GLOBAL GENERIC DRUGS MARKET SIZE, BY INHALATIONS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 32. GLOBAL GENERIC DRUGS MARKET SIZE, BY INJECTABLES, BY REGION, 2018-2032 (USD MILLION)
TABLE 33. GLOBAL GENERIC DRUGS MARKET SIZE, BY INJECTABLES, BY GROUP, 2018-2032 (USD MILLION)
TABLE 34. GLOBAL GENERIC DRUGS MARKET SIZE, BY INJECTABLES, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 35. GLOBAL GENERIC DRUGS MARKET SIZE, BY ORAL, BY REGION, 2018-2032 (USD MILLION)
TABLE 36. GLOBAL GENERIC DRUGS MARKET SIZE, BY ORAL, BY GROUP, 2018-2032 (USD MILLION)
TABLE 37. GLOBAL GENERIC DRUGS MARKET SIZE, BY ORAL, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 38. GLOBAL GENERIC DRUGS MARKET SIZE, BY TOPICAL, BY REGION, 2018-2032 (USD MILLION)
TABLE 39. GLOBAL GENERIC DRUGS MARKET SIZE, BY TOPICAL, BY GROUP, 2018-2032 (USD MILLION)
TABLE 40. GLOBAL GENERIC DRUGS MARKET SIZE, BY TOPICAL, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 41. GLOBAL GENERIC DRUGS MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
TABLE 42. GLOBAL GENERIC DRUGS MARKET SIZE, BY ADULT, BY REGION, 2018-2032 (USD MILLION)
TABLE 43. GLOBAL GENERIC DRUGS MARKET SIZE, BY ADULT, BY GROUP, 2018-2032 (USD MILLION)
TABLE 44. GLOBAL GENERIC DRUGS MARKET SIZE, BY ADULT, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 45. GLOBAL GENERIC DRUGS MARKET SIZE, BY GERIATRIC, BY REGION, 2018-2032 (USD MILLION)
TABLE 46. GLOBAL GENERIC DRUGS MARKET SIZE, BY GERIATRIC, BY GROUP, 2018-2032 (USD MILLION)
TABLE 47. GLOBAL GENERIC DRUGS MARKET SIZE, BY GERIATRIC, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 48. GLOBAL GENERIC DRUGS MARKET SIZE, BY PEDIATRIC, BY REGION, 2018-2032 (USD MILLION)
TABLE 49. GLOBAL GENERIC DRUGS MARKET SIZE, BY PEDIATRIC, BY GROUP, 2018-2032 (USD MILLION)
TABLE 50. GLOBAL GENERIC DRUGS MARKET SIZE, BY PEDIATRIC, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 51. GLOBAL GENERIC DRUGS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
TABLE 52. GLOBAL GENERIC DRUGS MARKET SIZE, BY CARDIOVASCULAR DISEASES, BY REGION, 2018-2032 (USD MILLION)
TABLE 53. GLOBAL GENERIC DRUGS MARKET SIZE, BY CARDIOVASCULAR DISEASES, BY GROUP, 2018-2032 (USD MILLION)
TABLE 54. GLOBAL GENERIC DRUGS MARKET SIZE, BY CARDIOVASCULAR DISEASES, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 55. GLOBAL GENERIC DRUGS MARKET SIZE, BY CARDIOVASCULAR DISEASES, 2018-2032 (USD MILLION)
TABLE 56. GLOBAL GENERIC DRUGS MARKET SIZE, BY HYPERTENSION, BY REGION, 2018-2032 (USD MILLION)
TABLE 57. GLOBAL GENERIC DRUGS MARKET SIZE, BY HYPERTENSION, BY GROUP, 2018-2032 (USD MILLION)
TABLE 58. GLOBAL GENERIC DRUGS MARKET SIZE, BY HYPERTENSION, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 59. GLOBAL GENERIC DRUGS MARKET SIZE, BY DYSLIPIDEMIA, BY REGION, 2018-2032 (USD MILLION)
TABLE 60. GLOBAL GENERIC DRUGS MARKET SIZE, BY DYSLIPIDEMIA, BY GROUP, 2018-2032 (USD MILLION)
TABLE 61. GLOBAL GENERIC DRUGS MARKET SIZE, BY DYSLIPIDEMIA, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 62. GLOBAL GENERIC DRUGS MARKET SIZE, BY HEART FAILURE, BY REGION, 2018-2032 (USD MILLION)
TABLE 63. GLOBAL GENERIC DRUGS MARKET SIZE, BY HEART FAILURE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 64. GLOBAL GENERIC DRUGS MARKET SIZE, BY HEART FAILURE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 65. GLOBAL GENERIC DRUGS MARKET SIZE, BY CENTRAL NERVOUS SYSTEM DISORDERS, BY REGION, 2018-2032 (USD MILLION)
TABLE 66. GLOBAL GENERIC DRUGS MARKET SIZE, BY CENTRAL NERVOUS SYSTEM DISORDERS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 67. GLOBAL GENERIC DRUGS MARKET SIZE, BY CENTRAL NERVOUS SYSTEM DISORDERS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 68. GLOBAL GENERIC DRUGS MARKET SIZE, BY CENTRAL NERVOUS SYSTEM DISORDERS, 2018-2032 (USD MILLION)
TABLE 69. GLOBAL GENERIC DRUGS MARKET SIZE, BY DEPRESSION & ANXIETY, BY REGION, 2018-2032 (USD MILLION)
TABLE 70. GLOBAL GENERIC DRUGS MARKET SIZE, BY DEPRESSION & ANXIETY, BY GROUP, 2018-2032 (USD MILLION)
TABLE 71. GLOBAL GENERIC DRUGS MARKET SIZE, BY DEPRESSION & ANXIETY, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 72. GLOBAL GENERIC DRUGS MARKET SIZE, BY EPILEPSY, BY REGION, 2018-2032 (USD MILLION)
TABLE 73. GLOBAL GENERIC DRUGS MARKET SIZE, BY EPILEPSY, BY GROUP, 2018-2032 (USD MILLION)
TABLE 74. GLOBAL GENERIC DRUGS MARKET SIZE, BY EPILEPSY, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 75. GLOBAL GENERIC DRUGS MARKET SIZE, BY SCHIZOPHRENIA & PSYCHOSIS, BY REGION, 2018-2032 (USD MILLION)
TABLE 76. GLOBAL GENERIC DRUGS MARKET SIZE, BY SCHIZOPHRENIA & PSYCHOSIS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 77. GLOBAL GENERIC DRUGS MARKET SIZE, BY SCHIZOPHRENIA & PSYCHOSIS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 78. GLOBAL GENERIC DRUGS MARKET SIZE, BY ONCOLOGY, BY REGION, 2018-2032 (USD MILLION)
TABLE 79. GLOBAL GENERIC DRUGS MARKET SIZE, BY ONCOLOGY, BY GROUP, 2018-2032 (USD MILLION)
TABLE 80. GLOBAL GENERIC DRUGS MARKET SIZE, BY ONCOLOGY, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 81. GLOBAL GENERIC DRUGS MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
TABLE 82. GLOBAL GENERIC DRUGS MARKET SIZE, BY SOLID TUMORS, BY REGION, 2018-2032 (USD MILLION)
TABLE 83. GLOBAL GENERIC DRUGS MARKET SIZE, BY SOLID TUMORS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 84. GLOBAL GENERIC DRUGS MARKET SIZE, BY SOLID TUMORS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 85. GLOBAL GENERIC DRUGS MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, BY REGION, 2018-2032 (USD MILLION)
TABLE 86. GLOBAL GENERIC DRUGS MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, BY GROUP, 2018-2032 (USD MILLION)
TABLE 87. GLOBAL GENERIC DRUGS MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 88. GLOBAL GENERIC DRUGS MARKET SIZE, BY ANTI-INFECTIVE DISEASES, BY REGION, 2018-2032 (USD MILLION)
TABLE 89. GLOBAL GENERIC DRUGS MARKET SIZE, BY ANTI-INFECTIVE DISEASES, BY GROUP, 2018-2032 (USD MILLION)
TABLE 90. GLOBAL GENERIC DRUGS MARKET SIZE, BY ANTI-INFECTIVE DISEASES, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 91. GLOBAL GENERIC DRUGS MARKET SIZE, BY ANTI-INFECTIVE DISEASES, 2018-2032 (USD MILLION)
TABLE 92. GLOBAL GENERIC DRUGS MARKET SIZE, BY BACTERIAL INFECTIONS, BY REGION, 2018-2032 (USD MILLION)
TABLE 93. GLOBAL GENERIC DRUGS MARKET SIZE, BY BACTERIAL INFECTIONS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 94. GLOBAL GENERIC DRUGS MARKET SIZE, BY BACTERIAL INFECTIONS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 95. GLOBAL GENERIC DRUGS MARKET SIZE, BY VIRAL INFECTIONS, BY REGION, 2018-2032 (USD MILLION)
TABLE 96. GLOBAL GENERIC DRUGS MARKET SIZE, BY VIRAL INFECTIONS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 97. GLOBAL GENERIC DRUGS MARKET SIZE, BY VIRAL INFECTIONS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 98. GLOBAL GENERIC DRUGS MARKET SIZE, BY FUNGAL INFECTIONS, BY REGION, 2018-2032 (USD MILLION)
TABLE 99. GLOBAL GENERIC DRUGS MARKET SIZE, BY FUNGAL INFECTIONS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 100. GLOBAL GENERIC DRUGS MARKET SIZE, BY FUNGAL INFECTIONS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 101. GLOBAL GENERIC DRUGS MARKET SIZE, BY PARASITIC INFECTIONS, BY REGION, 2018-2032 (USD MILLION)
TABLE 102. GLOBAL GENERIC DRUGS MARKET SIZE, BY PARASITIC INFECTIONS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 103. GLOBAL GENERIC DRUGS MARKET SIZE, BY PARASITIC INFECTIONS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 104. GLOBAL GENERIC DRUGS MARKET SIZE, BY RESPIRATORY DISEASES, BY REGION, 2018-2032 (USD MILLION)
TABLE 105. GLOBAL GENERIC DRUGS MARKET SIZE, BY RESPIRATORY DISEASES, BY GROUP, 2018-2032 (USD MILLION)
TABLE 106. GLOBAL GENERIC DRUGS MARKET SIZE, BY RESPIRATORY DISEASES, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 107. GLOBAL GENERIC DRUGS MARKET SIZE, BY RESPIRATORY DISEASES, 2018-2032 (USD MILLION)
TABLE 108. GLOBAL GENERIC DRUGS MARKET SIZE, BY ASTHMA, BY REGION, 2018-2032 (USD MILLION)
TABLE 109. GLOBAL GENERIC DRUGS MARKET SIZE, BY ASTHMA, BY GROUP, 2018-2032 (USD MILLION)
TABLE 110. GLOBAL GENERIC DRUGS MARKET SIZE, BY ASTHMA, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 111. GLOBAL GENERIC DRUGS MARKET SIZE, BY CHRONIC OBSTRUCTIVE PULMONARY DISEASE, BY REGION, 2018-2032 (USD MILLION)
TABLE 112. GLOBAL GENERIC DRUGS MARKET SIZE, BY CHRONIC OBSTRUCTIVE PULMONARY DISEASE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 113. GLOBAL GENERIC DRUGS MARKET SIZE, BY CHRONIC OBSTRUCTIVE PULMONARY DISEASE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 114. GLOBAL GENERIC DRUGS MARKET SIZE, BY ALLERGIC RHINITIS, BY REGION, 2018-2032 (USD MILLION)
TABLE 115. GLOBAL GENERIC DRUGS MARKET SIZE, BY ALLERGIC RHINITIS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 116. GLOBAL GENERIC DRUGS MARKET SIZE, BY ALLERGIC RHINITIS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 117. GLOBAL GENERIC DRUGS MARKET SIZE, BY GASTROINTESTINAL DISORDERS, BY REGION, 2018-2032 (USD MILLION)
TABLE 118. GLOBAL GENERIC DRUGS MARKET SIZE, BY GASTROINTESTINAL DISORDERS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 119. GLOBAL GENERIC DRUGS MARKET SIZE, BY GASTROINTESTINAL DISORDERS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 120. GLOBAL GENERIC DRUGS MARKET SIZE, BY DERMATOLOGICAL DISORDERS, BY REGION, 2018-2032 (USD MILLION)
TABLE 121. GLOBAL GENERIC DRUGS MARKET SIZE, BY DERMATOLOGICAL DISORDERS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 122. GLOBAL GENERIC DRUGS MARKET SIZE, BY DERMATOLOGICAL DISORDERS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 123. GLOBAL GENERIC DRUGS MARKET SIZE, BY HEMATOLOGY, BY REGION, 2018-2032 (USD MILLION)
TABLE 124. GLOBAL GENERIC DRUGS MARKET SIZE, BY HEMATOLOGY, BY GROUP, 2018-2032 (USD MILLION)
TABLE 125. GLOBAL GENERIC DRUGS MARKET SIZE, BY HEMATOLOGY, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 126. GLOBAL GENERIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 127. GLOBAL GENERIC DRUGS MARKET SIZE, BY OFFLINE, BY REGION, 2018-2032 (USD MILLION)
TABLE 128. GLOBAL GENERIC DRUGS MARKET SIZE, BY OFFLINE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 129. GLOBAL GENERIC DRUGS MARKET SIZE, BY OFFLINE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 130. GLOBAL GENERIC DRUGS MARKET SIZE, BY OFFLINE, 2018-2032 (USD MILLION)
TABLE 131. GLOBAL GENERIC DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
TABLE 132. GLOBAL GENERIC DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
TABLE 133. GLOBAL GENERIC DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 134. GLOBAL GENERIC DRUGS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
TABLE 135. GLOBAL GENERIC DRUGS MARKET SIZE, BY RETAIL PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
TABLE 136. GLOBAL GENERIC DRUGS MARKET SIZE, BY RETAIL PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 137. GLOBAL GENERIC DRUGS MARKET SIZE, BY ONLINE, BY REGION, 2018-2032 (USD MILLION)
TABLE 138. GLOBAL GENERIC DRUGS MARKET SIZE, BY ONLINE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 139. GLOBAL GENERIC DRUGS MARKET SIZE, BY ONLINE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 140. GLOBAL GENERIC DRUGS MARKET SIZE, BY ONLINE, 2018-2032 (USD MILLION)
TABLE 141. GLOBAL GENERIC DRUGS MARKET SIZE, BY BUSINESS-TO-BUSINESS PLATFORMS, BY REGION, 2018-2032 (USD MILLION)
TABLE 142. GLOBAL GENERIC DRUGS MARKET SIZE, BY BUSINESS-TO-BUSINESS PLATFORMS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 143. GLOBAL GENERIC DRUGS MARKET SIZE, BY BUSINESS-TO-BUSINESS PLATFORMS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 144. GLOBAL GENERIC DRUGS MARKET SIZE, BY BUSINESS-TO-CONSUMER PLATFORMS, BY REGION, 2018-2032 (USD MILLION)
TABLE 145. GLOBAL GENERIC DRUGS MARKET SIZE, BY BUSINESS-TO-CONSUMER PLATFORMS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 146. GLOBAL GENERIC DRUGS MARKET SIZE, BY BUSINESS-TO-CONSUMER PLATFORMS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 147. GLOBAL GENERIC DRUGS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 148. AMERICAS GENERIC DRUGS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
TABLE 149. AMERICAS GENERIC DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
TABLE 150. AMERICAS GENERIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 151. AMERICAS GENERIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 152. AMERICAS GENERIC DRUGS MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
TABLE 153. AMERICAS GENERIC DRUGS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
TABLE 154. AMERICAS GENERIC DRUGS MARKET SIZE, BY CARDIOVASCULAR DISEASES, 2018-2032 (USD MILLION)
TABLE 155. AMERICAS GENERIC DRUGS MARKET SIZE, BY CENTRAL NERVOUS SYSTEM DISORDERS, 2018-2032 (USD MILLION)
TABLE 156. AMERICAS GENERIC DRUGS MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
TABLE 157. AMERICAS GENERIC DRUGS MARKET SIZE, BY ANTI-INFECTIVE DISEASES, 2018-2032 (USD MILLION)
TABLE 158. AMERICAS GENERIC DRUGS MARKET SIZE, BY RESPIRATORY DISEASES, 2018-2032 (USD MILLION)
TABLE 159. AMERICAS GENERIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 160. AMERICAS GENERIC DRUGS MARKET SIZE, BY OFFLINE, 2018-2032 (USD MILLION)
TABLE 161. AMERICAS GENERIC DRUGS MARKET SIZE, BY ONLINE, 2018-2032 (USD MILLION)
TABLE 162. NORTH AMERICA GENERIC DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 163. NORTH AMERICA GENERIC DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
TABLE 164. NORTH AMERICA GENERIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 165. NORTH AMERICA GENERIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 166. NORTH AMERICA GENERIC DRUGS MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
TABLE 167. NORTH AMERICA GENERIC DRUGS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
TABLE 168. NORTH AMERICA GENERIC DRUGS MARKET SIZE, BY CARDIOVASCULAR DISEASES, 2018-2032 (USD MILLION)
TABLE 169. NORTH AMERICA GENERIC DRUGS MARKET SIZE, BY CENTRAL NERVOUS SYSTEM DISORDERS, 2018-2032 (USD MILLION)
TABLE 170. NORTH AMERICA GENERIC DRUGS MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
TABLE 171. NORTH AMERICA GENERIC DRUGS MARKET SIZE, BY ANTI-INFECTIVE DISEASES, 2018-2032 (USD MILLION)
TABLE 172. NORTH AMERICA GENERIC DRUGS MARKET SIZE, BY RESPIRATORY DISEASES, 2018-2032 (USD MILLION)
TABLE 173. NORTH AMERICA GENERIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 174. NORTH AMERICA GENERIC DRUGS MARKET SIZE, BY OFFLINE, 2018-2032 (USD MILLION)
TABLE 175. NORTH AMERICA GENERIC DRUGS MARKET SIZE, BY ONLINE, 2018-2032 (USD MILLION)
TABLE 176. LATIN AMERICA GENERIC DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 177. LATIN AMERICA GENERIC DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
TABLE 178. LATIN AMERICA GENERIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 179. LATIN AMERICA GENERIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 180. LATIN AMERICA GENERIC DRUGS MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
TABLE 181. LATIN AMERICA GENERIC DRUGS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
TABLE 182. LATIN AMERICA GENERIC DRUGS MARKET SIZE, BY CARDIOVASCULAR DISEASES, 2018-2032 (USD MILLION)
TABLE 183. LATIN AMERICA GENERIC DRUGS MARKET SIZE, BY CENTRAL NERVOUS SYSTEM DISORDERS, 2018-2032 (USD MILLION)
TABLE 184. LATIN AMERICA GENERIC DRUGS MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
TABLE 185. LATIN AMERICA GENERIC DRUGS MARKET SIZE, BY ANTI-INFECTIVE DISEASES, 2018-2032 (USD MILLION)
TABLE 186. LATIN AMERICA GENERIC DRUGS MARKET SIZE, BY RESPIRATORY DISEASES, 2018-2032 (USD MILLION)
TABLE 187. LATIN AMERICA GENERIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 188. LATIN AMERICA GENERIC DRUGS MARKET SIZE, BY OFFLINE, 2018-2032 (USD MILLION)
TABLE 189. LATIN AMERICA GENERIC DRUGS MARKET SIZE, BY ONLINE, 2018-2032 (USD MILLION)
TABLE 190. EUROPE, MIDDLE EAST & AFRICA GENERIC DRUGS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
TABLE 191. EUROPE, MIDDLE EAST & AFRICA GENERIC DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
TABLE 192. EUROPE, MIDDLE EAST & AFRICA GENERIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 193. EUROPE, MIDDLE EAST & AFRICA GENERIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 194. EUROPE, MIDDLE EAST & AFRICA GENERIC DRUGS MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
TABLE 195. EUROPE, MIDDLE EAST & AFRICA GENERIC DRUGS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
TABLE 196. EUROPE, MIDDLE EAST & AFRICA GENERIC DRUGS MARKET SIZE, BY CARDIOVASCULAR DISEASES, 2018-2032 (USD MILLION)
TABLE 197. EUROPE, MIDDLE EAST & AFRICA GENERIC DRUGS MARKET SIZE, BY CENTRAL NERVOUS SYSTEM DISORDERS, 2018-2032 (USD MILLION)
TABLE 198. EUROPE, MIDDLE EAST & AFRICA GENERIC DRUGS MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
TABLE 199. EUROPE, MIDDLE EAST & AFRICA GENERIC DRUGS MARKET SIZE, BY ANTI-INFECTIVE DISEASES, 2018-2032 (USD MILLION)
TABLE 200. EUROPE, MIDDLE EAST & AFRICA GENERIC DRUGS MARKET SIZE, BY RESPIRATORY DISEASES, 2018-2032 (USD MILLION)
TABLE 201. EUROPE, MIDDLE EAST & AFRICA GENERIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 202. EUROPE, MIDDLE EAST & AFRICA GENERIC DRUGS MARKET SIZE, BY OFFLINE, 2018-2032 (USD MILLION)
TABLE 203. EUROPE, MIDDLE EAST & AFRICA GENERIC DRUGS MARKET SIZE, BY ONLINE, 2018-2032 (USD MILLION)
TABLE 204. EUROPE GENERIC DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 205. EUROPE GENERIC DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
TABLE 206. EUROPE GENERIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 207. EUROPE GENERIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 208. EUROPE GENERIC DRUGS MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
TABLE 209. EUROPE GENERIC DRUGS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
TABLE 210. EUROPE GENERIC DRUGS MARKET SIZE, BY CARDIOVASCULAR DISEASES, 2018-2032 (USD MILLION)
TABLE 211. EUROPE GENERIC DRUGS MARKET SIZE, BY CENTRAL NERVOUS SYSTEM DISORDERS, 2018-2032 (USD MILLION)
TABLE 212. EUROPE GENERIC DRUGS MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
TABLE 213. EUROPE GENERIC DRUGS MARKET SIZE, BY ANTI-INFECTIVE DISEASES, 2018-2032 (USD MILLION)
TABLE 214. EUROPE GENERIC DRUGS MARKET SIZE, BY RESPIRATORY DISEASES, 2018-2032 (USD MILLION)
TABLE 215. EUROPE GENERIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 216. EUROPE GENERIC DRUGS MARKET SIZE, BY OFFLINE, 2018-2032 (USD MILLION)
TABLE 217. EUROPE GENERIC DRUGS MARKET SIZE, BY ONLINE, 2018-2032 (USD MILLION)
TABLE 218. MIDDLE EAST GENERIC DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 219. MIDDLE EAST GENERIC DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
TABLE 220. MIDDLE EAST GENERIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 221. MIDDLE EAST GENERIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 222. MIDDLE EAST GENERIC DRUGS MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
TABLE 223. MIDDLE EAST GENERIC DRUGS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
TABLE 224. MIDDLE EAST GENERIC DRUGS MARKET SIZE, BY CARDIOVASCULAR DISEASES, 2018-2032 (USD MILLION)
TABLE 225. MIDDLE EAST GENERIC DRUGS MARKET SIZE, BY CENTRAL NERVOUS SYSTEM DISORDERS, 2018-2032 (USD MILLION)
TABLE 226. MIDDLE EAST GENERIC DRUGS MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
TABLE 227. MIDDLE EAST GENERIC DRUGS MARKET SIZE, BY ANTI-INFECTIVE DISEASES, 2018-2032 (USD MILLION)
TABLE 228. MIDDLE EAST GENERIC DRUGS MARKET SIZE, BY RESPIRATORY DISEASES, 2018-2032 (USD MILLION)
TABLE 229. MIDDLE EAST GENERIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 230. MIDDLE EAST GENERIC DRUGS MARKET SIZE, BY OFFLINE, 2018-2032 (USD MILLION)
TABLE 231. MIDDLE EAST GENERIC DRUGS MARKET SIZE, BY ONLINE, 2018-2032 (USD MILLION)
TABLE 232. AFRICA GENERIC DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 233. AFRICA GENERIC DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
TABLE 234. AFRICA GENERIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 235. AFRICA GENERIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 236. AFRICA GENERIC DRUGS MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
TABLE 237. AFRICA GENERIC DRUGS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
TABLE 238. AFRICA GENERIC DRUGS MARKET SIZE, BY CARDIOVASCULAR DISEASES, 2018-2032 (USD MILLION)
TABLE 239. AFRICA GENERIC DRUGS MARKET SIZE, BY CENTRAL NERVOUS SYSTEM DISORDERS, 2018-2032 (USD MILLION)
TABLE 240. AFRICA GENERIC DRUGS MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
TABLE 241. AFRICA GENERIC DRUGS MARKET SIZE, BY ANTI-INFECTIVE DISEASES, 2018-2032 (USD MILLION)
TABLE 242. AFRICA GENERIC DRUGS MARKET SIZE, BY RESPIRATORY DISEASES, 2018-2032 (USD MILLION)
TABLE 243. AFRICA GENERIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 244. AFRICA GENERIC DRUGS MARKET SIZE, BY OFFLINE, 2018-2032 (USD MILLION)
TABLE 245. AFRICA GENERIC DRUGS MARKET SIZE, BY ONLINE, 2018-2032 (USD MILLION)
TABLE 246. ASIA-PACIFIC GENERIC DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 247. ASIA-PACIFIC GENERIC DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
TABLE 248. ASIA-PACIFIC GENERIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 249. ASIA-PACIFIC GENERIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 250. ASIA-PACIFIC GENERIC DRUGS MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
TABLE 251. ASIA-PACIFIC GENERIC DRUGS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
TABLE 252. ASIA-PACIFIC GENERIC DRUGS MARKET SIZE, BY CARDIOVASCULAR DISEASES, 2018-2032 (USD MILLION)
TABLE 253. ASIA-PACIFIC GENERIC DRUGS MARKET SIZE, BY CENTRAL NERVOUS SYSTEM DISORDERS, 2018-2032 (USD MILLION)
TABLE 254. ASIA-PACIFIC GENERIC DRUGS MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
TABLE 255. ASIA-PACIFIC GENERIC DRUGS MARKET SIZE, BY ANTI-INFECTIVE DISEASES, 2018-2032 (USD MILLION)
TABLE 256. ASIA-PACIFIC GENERIC DRUGS MARKET SIZE, BY RESPIRATORY DISEASES, 2018-2032 (USD MILLION)
TABLE 257. ASIA-PACIFIC GENERIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 258. ASIA-PACIFIC GENERIC DRUGS MARKET SIZE, BY OFFLINE, 2018-2032 (USD MILLION)
TABLE 259. ASIA-PACIFIC GENERIC DRUGS MARKET SIZE, BY ONLINE, 2018-2032 (USD MILLION)
TABLE 260. GLOBAL GENERIC DRUGS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 261. ASEAN GENERIC DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 262. ASEAN GENERIC DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
TABLE 263. ASEAN GENERIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 264. ASEAN GENERIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 265. ASEAN GENERIC DRUGS MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
TABLE 266. ASEAN GENERIC DRUGS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
TABLE 267. ASEAN GENERIC DRUGS MARKET SIZE, BY CARDIOVASCULAR DISEASES, 2018-2032 (USD MILLION)
TABLE 268. ASEAN GENERIC DRUGS MARKET SIZE, BY CENTRAL NERVOUS SYSTEM DISORDERS, 2018-2032 (USD MILLION)
TABLE 269. ASEAN GENERIC DRUGS MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
TABLE 270. ASEAN GENERIC DRUGS MARKET SIZE, BY ANTI-INFECTIVE DISEASES, 2018-2032 (USD MILLION)
TABLE 271. ASEAN GENERIC DRUGS MARKET SIZE, BY RESPIRATORY DISEASES, 2018-2032 (USD MILLION)
TABLE 272. ASEAN GENERIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 273. ASEAN GENERIC DRUGS MARKET SIZE, BY OFFLINE, 2018-2032 (USD MILLION)
TABLE 274. ASEAN GENERIC DRUGS MARKET SIZE, BY ONLINE, 2018-2032 (USD MILLION)
TABLE 275. GCC GENERIC DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 276. GCC GENERIC DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
TABLE 277. GCC GENERIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 278. GCC GENERIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 279. GCC GENERIC DRUGS MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
TABLE 280. GCC GENERIC DRUGS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
TABLE 281. GCC GENERIC DRUGS MARKET SIZE, BY CARDIOVASCULAR DISEASES, 2018-2032 (USD MILLION)
TABLE 282. GCC GENERIC DRUGS MARKET SIZE, BY CENTRAL NERVOUS SYSTEM DISORDERS, 2018-2032 (USD MILLION)
TABLE 283. GCC GENERIC DRUGS MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
TABLE 284. GCC GENERIC DRUGS MARKET SIZE, BY ANTI-INFECTIVE DISEASES, 2018-2032 (USD MILLION)
TABLE 285. GCC GENERIC DRUGS MARKET SIZE, BY RESPIRATORY DISEASES, 2018-2032 (USD MILLION)
TABLE 286. GCC GENERIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 287. GCC GENERIC DRUGS MARKET SIZE, BY OFFLINE, 2018-2032 (USD MILLION)
TABLE 288. GCC GENERIC DRUGS MARKET SIZE, BY ONLINE, 2018-2032 (USD MILLION)
TABLE 289. EUROPEAN UNION GENERIC DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 290. EUROPEAN UNION GENERIC DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
TABLE 291. EUROPEAN UNION GENERIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 292. EUROPEAN UNION GENERIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 293. EUROPEAN UNION GENERIC DRUGS MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
TABLE 294. EUROPEAN UNION GENERIC DRUGS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
TABLE 295. EUROPEAN UNION GENERIC DRUGS MARKET SIZE, BY CARDIOVASCULAR DISEASES, 2018-2032 (USD MILLION)
TABLE 296. EUROPEAN UNION GENERIC DRUGS MARKET SIZE, BY CENTRAL NERVOUS SYSTEM DISORDERS, 2018-2032 (USD MILLION)
TABLE 297. EUROPEAN UNION GENERIC DRUGS MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
TABLE 298. EUROPEAN UNION GENERIC DRUGS MARKET SIZE, BY ANTI-INFECTIVE DISEASES, 2018-2032 (USD MILLION)
TABLE 299. EUROPEAN UNION GENERIC DRUGS MARKET SIZE, BY RESPIRATORY DISEASES, 2018-2032 (USD MILLION)
TABLE 300. EUROPEAN UNION GENERIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 301. EUROPEAN UNION GENERIC DRUGS MARKET SIZE, BY OFFLINE, 2018-2032 (USD MILLION)
TABLE 302. EUROPEAN UNION GENERIC DRUGS MARKET SIZE, BY ONLINE, 2018-2032 (USD MILLION)
TABLE 303. BRICS GENERIC DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 304. BRICS GENERIC DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
TABLE 305. BRICS GENERIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 306. BRICS GENERIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 307. BRICS GENERIC DRUGS MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
TABLE 308. BRICS GENERIC DRUGS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
TABLE 309. BRICS GENERIC DRUGS MARKET SIZE, BY CARDIOVASCULAR DISEASES, 2018-2032 (USD MILLION)
TABLE 310. BRICS GENERIC DRUGS MARKET SIZE, BY CENTRAL NERVOUS SYSTEM DISORDERS, 2018-2032 (USD MILLION)
TABLE 311. BRICS GENERIC DRUGS MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
TABLE 312. BRICS GENERIC DRUGS MARKET SIZE, BY ANTI-INFECTIVE DISEASES, 2018-2032 (USD MILLION)
TABLE 313. BRICS GENERIC DRUGS MARKET SIZE, BY RESPIRATORY DISEASES, 2018-2032 (USD MILLION)
TABLE 314. BRICS GENERIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 315. BRICS GENERIC DRUGS MARKET SIZE, BY OFFLINE, 2018-2032 (USD MILLION)
TABLE 316. BRICS GENERIC DRUGS MARKET SIZE, BY ONLINE, 2018-2032 (USD MILLION)
TABLE 317. G7 GENERIC DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 318. G7 GENERIC DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
TABLE 319. G7 GENERIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 320. G7 GENERIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 321. G7 GENERIC DRUGS MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
TABLE 322. G7 GENERIC DRUGS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
TABLE 323. G7 GENERIC DRUGS MARKET SIZE, BY CARDIOVASCULAR DISEASES, 2018-2032 (USD MILLION)
TABLE 324. G7 GENERIC DRUGS MARKET SIZE, BY CENTRAL NERVOUS SYSTEM DISORDERS, 2018-2032 (USD MILLION)
TABLE 325. G7 GENERIC DRUGS MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
TABLE 326. G7 GENERIC DRUGS MARKET SIZE, BY ANTI-INFECTIVE DISEASES, 2018-2032 (USD MILLION)
TABLE 327. G7 GENERIC DRUGS MARKET SIZE, BY RESPIRATORY DISEASES, 2018-2032 (USD MILLION)
TABLE 328. G7 GENERIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 329. G7 GENERIC DRUGS MARKET SIZE, BY OFFLINE, 2018-2032 (USD MILLION)
TABLE 330. G7 GENERIC DRUGS MARKET SIZE, BY ONLINE, 2018-2032 (USD MILLION)
TABLE 331. NATO GENERIC DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 332. NATO GENERIC DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
TABLE 333. NATO GENERIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 334. NATO GENERIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 335. NATO GENERIC DRUGS MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
TABLE 336. NATO GENERIC DRUGS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
TABLE 337. NATO GENERIC DRUGS MARKET SIZE, BY CARDIOVASCULAR DISEASES, 2018-2032 (USD MILLION)
TABLE 338. NATO GENERIC DRUGS MARKET SIZE, BY CENTRAL NERVOUS SYSTEM DISORDERS, 2018-2032 (USD MILLION)
TABLE 339. NATO GENERIC DRUGS MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
TABLE 340. NATO GENERIC DRUGS MARKET SIZE, BY ANTI-INFECTIVE DISEASES, 2018-2032 (USD MILLION)
TABLE 341. NATO GENERIC DRUGS MARKET SIZE, BY RESPIRATORY DISEASES, 2018-2032 (USD MILLION)
TABLE 342. NATO GENERIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MIL

Companies Mentioned

The key companies profiled in this Generic Drugs market report include:
  • Abbott Laboratories
  • Alembic Pharmaceuticals Limited
  • Alkem Laboratories Limited
  • Amneal Pharmaceuticals, Inc.
  • Aspen Pharmacare Holdings Limited
  • Aurobindo Pharma Limited
  • Bausch Health Companies Inc.
  • Baxter International Inc.
  • Biocon Limited
  • Bora Pharmaceuticals Co. Ltd
  • Cipla Limited
  • Dr. Reddy’s Laboratories Ltd.
  • Eli Lilly and Company
  • Endo, Inc.
  • Fresenius SE & Co. KGaA
  • GlaxoSmithKline PLC
  • Glenmark Pharmaceuticals Limited
  • Hikma Pharmaceuticals PLC
  • Intas Pharmaceuticals Ltd.
  • Krka, d. d.
  • Lotus Pharmaceutical Co. Ltd
  • Lupin Limited
  • Pfizer, Inc.
  • Sandoz Group AG
  • Sanofi SA
  • STADA Arzneimittel AG
  • Sun Pharmaceutical Industries Limited
  • Teva Pharmaceutical Industries Ltd.
  • Viatris Inc.
  • Zydus Lifesciences Limited

Table Information

Report AttributeDetails
No. of Pages194
PublishedJanuary 2026
Forecast Period2025 - 2032
Estimated Market Value ( USD ) in 2025 $ 392.73 Billion
Forecasted Market Value ( USD ) by 2032 $ 731.02 Billion
Compound Annual Growth Rate9.2%
Regions CoveredGlobal
No. of Companies Mentioned31

Related Topics

Related Reports

United States Generic Drugs Market Size and Share Analysis - Growth Trends and Forecast Report 2025-2033 - Product Image

United States Generic Drugs Market Size and Share Analysis - Growth Trends and Forecast Report 2025-2033

  • Report
  • 200 Pages
  • United States
From
North America Generic Drugs Market Report and Forecast (2025-2034) - Product Image

North America Generic Drugs Market Report and Forecast (2025-2034)

  • Report
  • 250 Pages
  • North America
From
Patent Strategies for Generic Medicines and Generic Medicine Companies Training Course (March 17, 2026) - Product Image

Patent Strategies for Generic Medicines and Generic Medicine Companies Training Course (March 17, 2026)

  • Training
  • 1 Day
  • Global
Inhalation & Nasal Sprays Generic Drugs Market - Global Forecast 2026-2032 - Product Image

Inhalation & Nasal Sprays Generic Drugs Market - Global Forecast 2026-2032

  • Report
  • 181 Pages
  • Global
From
Specialty Generics Market Report 2025 - Product Image

Specialty Generics Market Report 2025

  • Report
  • 250 Pages
  • Global
From

About the Generic Drugs Market

The Generic Drugs market is a segment of the pharmaceutical industry that focuses on the production and sale of generic drugs. Generic drugs are copies of brand-name drugs that have the same active ingredients, dosage form, strength, route of administration, safety, efficacy, and intended use as the original drug. Generic drugs are typically much cheaper than their brand-name counterparts, making them a popular choice for consumers. Generic drugs are produced by a variety of companies, including large pharmaceutical companies, small generic drug manufacturers, and even generic drug divisions of brand-name drug companies. Generic drug companies must meet the same standards of quality, safety, and efficacy as brand-name drug companies. Some of the major companies in the Generic Drugs market include Teva Pharmaceuticals, Mylan, Sandoz, Sun Pharmaceuticals, Dr. Reddy's Laboratories, and Lupin. Show Less Read more

Copyright © 2002-2026 Research and Markets. All Rights Reserved.